Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identifying best practices for RTTs and dosimetrists: a Delphi consensus study on standardizing workflows in proton therapy.

Technical innovations & patient support in radiation oncology·2026

Same author

Norwegian general population normative data for the European Organization for Research and Treatment of Cancer questionnaires: the Quality of Life Questionnaire-Core 30, the Sexual Health Questionnaire QLQ-SHQ22 and the sexual domains of the QLQ-BR23/BR45.

European journal of cancer (Oxford, England : 1990)·2023

Same author

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool.

Thrombosis research·2023

Same author

Impact of early inoculation of probiotics to suckling piglets on postweaning diarrhoea - A challenge study with Enterotoxigenic E. Coli F18.

Animal : an international journal of animal bioscience·2022

Same author

Trait mindfulness and the mental and physical health of caregivers for individuals with cancer.

European journal of integrative medicine·2021

Same author

Functional in vitro screening of probiotic strains for inoculation of piglets as a prophylactic measure towards Enterotoxigenic Escherichia coli infection.

Journal of microbiological methods·2020

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

DNA polymorphisms of the apolipoprotein B gene (XbaI, EcoRI, and MspI RFLPs) in Norwegians at risk of atherosclerosis

M Delghandi¹, R Thangarajah, M Nilsen

¹Department of Morphology, University of Tromsø, Norway. madjid@fagmed.uit.no

Acta Cardiologica

|October 8, 1999

Summary

This summary is machine-generated.

Genetic variations in apolipoprotein B (apo B) influence lipid levels and atherosclerosis risk. Specific MspI genotypes and haplotypes correlate with altered total cholesterol and LDL cholesterol in Norwegian subjects.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes

Published on: July 17, 2021

Related Experiment Videos

Last Updated: Jun 17, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes

Published on: July 17, 2021

Area of Science:

Genetics
Biochemistry
Cardiovascular Disease

Background:

Apolipoprotein B (apo B) is crucial for low-density lipoprotein (LDL) structure and receptor binding.
Apolipoprotein B gene polymorphisms have been linked to variations in serum lipid levels across populations.
Understanding these genetic associations is vital for assessing atherosclerosis risk.

Purpose of the Study:

To investigate the frequency of XbaI, EcoRI, and MspI polymorphisms in the apo B gene.
To determine the influence of these polymorphisms and their haplotypes on lipid levels in Norwegians.
To assess the association between apo B gene variations and atherosclerosis risk.

Main Methods:

Genotyping of XbaI, EcoRI, and MspI restriction sites in the apo B gene.
Analysis of serum lipid levels, including total cholesterol (TC) and LDL cholesterol (LDLC).
Statistical association studies between apo B genotypes, haplotypes, and lipid profiles in cases and controls.

Main Results:

The M allele of MspI was more frequent in cases with high TC, LDLC, and apo B.
MspI genotypes showed a significant association with TC, LDLC, and apo B levels in cases.
Haplotypes with specific amino acid changes (Lys/Arg) were linked to lower serum lipids in at-risk individuals.

Conclusions:

Variations in the apo B gene, particularly those altering charged amino acids, impact circulating blood lipids.
These genetic variations may contribute to the risk of developing atherosclerosis.
The study highlights the role of specific apo B gene polymorphisms in lipid metabolism and cardiovascular risk.